Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. Academic Article

abstract

• Six dogs were entered into a 30-day, prospective, nonrandomized, uncontrolled clinical trial evaluating the effects of an oral preparation of budesonide on the hypothalamic-pituitary-adrenal (HPA) axis during therapeutic management of active inflammatory bowel disease. Oral budesonide, at a dose of 3 mg/m(2), was administered once daily. Upon entry and completion of the trial, serum basal cortisol, adrenocorticotropic (ACTH)-stimulated cortisol, endogenous ACTH concentration, serum alkaline phosphatase (SAP) activity, and urine specific gravity were evaluated, as well as owner assessment of glucocorticoid-associated side effects. Significant suppression of the HPA axis occurred. No significant differences in SAP activity, urine specific gravity, or owner-subjective assessments were detected.

authors

• Steiner, Joerg

published proceedings

• J Am Anim Hosp Assoc

author list (cited authors)

• Tumulty, J. W., Broussard, J. D., Steiner, J. M., Peterson, M. E., & Williams, D. A.

citation count

• 20

complete list of authors

• Tumulty, Joshua W||Broussard, John D||Steiner, Jörg M||Peterson, Mark E||Williams, David A

publication date

• March 2004

publisher

• American Animal Hospital Association  Publisher

published in

• Journal of the American Animal Hospital Association  Journal

keywords

• Adrenocorticotropic Hormone
• Alkaline Phosphatase
• Animals
• Anti-Inflammatory Agents
• Budesonide
• Dog Diseases
• Dogs
• Hydrocortisone
• Inflammatory Bowel Diseases
• Pituitary-Adrenal System
• Pituitary-adrenal Function Tests
• Prospective Studies
• Treatment Outcome
• Urinalysis

PubMed Central ID

• 15007047

Digital Object Identifier (DOI)

• 10.5326/0400120

start page

• 120

end page

• 123

volume

• 40

issue

• 2

URL

• http%3A%2F%2Fdx.doi.org%2F10.5326%2F0400120